Russell Investments Group Ltd. lowered its position in Spark Therapeutics, Inc. (NASDAQ:ONCE) by 20.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,893 shares of the biotechnology company’s stock after selling 3,573 shares during the period. Russell Investments Group Ltd.’s holdings in Spark Therapeutics were worth $741,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of ONCE. State Street Corp increased its stake in shares of Spark Therapeutics by 12.4% in the fourth quarter. State Street Corp now owns 902,606 shares of the biotechnology company’s stock valued at $45,044,000 after buying an additional 99,792 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Spark Therapeutics by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 185,036 shares of the biotechnology company’s stock valued at $9,233,000 after buying an additional 10,616 shares in the last quarter. Norges Bank bought a new stake in shares of Spark Therapeutics during the fourth quarter valued at about $8,232,000. Guggenheim Capital LLC bought a new stake in shares of Spark Therapeutics during the fourth quarter valued at about $2,413,000. Finally, Teachers Advisors LLC increased its stake in shares of Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 4,875 shares in the last quarter. Institutional investors own 88.96% of the company’s stock.
Shares of Spark Therapeutics, Inc. (ONCE) opened at 64.16 on Thursday. The firm’s 50-day moving average price is $58.71 and its 200 day moving average price is $57.93. The firm’s market capitalization is $2.00 billion. Spark Therapeutics, Inc. has a 52 week low of $35.07 and a 52 week high of $65.99.
Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by $0.34. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.35 million. Spark Therapeutics had a negative return on equity of 44.06% and a negative net margin of 745.48%. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. On average, analysts anticipate that Spark Therapeutics, Inc. will post ($6.86) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://baseballnewssource.com/markets/spark-therapeutics-inc-nasdaqonce-shares-sold-by-russell-investments-group-ltd-updated-updated/1115020.html.
Several analysts have recently issued reports on ONCE shares. UBS AG started coverage on Spark Therapeutics in a research report on Wednesday, March 29th. They issued a “buy” rating and a $70.00 price objective on the stock. Jefferies Group LLC initiated coverage on Spark Therapeutics in a research report on Monday, July 10th. They issued a “buy” rating and a $85.00 price objective on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $76.00 target price on shares of Spark Therapeutics in a research report on Monday, April 10th. Cantor Fitzgerald set a $94.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Finally, BidaskClub upgraded Spark Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. Spark Therapeutics has a consensus rating of “Buy” and a consensus target price of $70.17.
In related news, CFO Stephen W. Webster sold 1,898 shares of the business’s stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $55.00, for a total transaction of $104,390.00. Following the transaction, the chief financial officer now directly owns 4,398 shares in the company, valued at $241,890. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Katherine A. High sold 2,060 shares of the business’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $55.01, for a total value of $113,320.60. Following the transaction, the insider now owns 212,060 shares in the company, valued at $11,665,420.60. The disclosure for this sale can be found here. Insiders have sold 87,423 shares of company stock worth $5,210,666 over the last 90 days. Corporate insiders own 7.30% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with our FREE daily email newsletter.